Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PGK1 | P00558 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30560023 | 1.00 | LMNA (0.44) | LMNASLC29A1ADORA3ADORA1CDK1 | |
| SCHEMBL20164730 | 0.86 | YTHDC1 (0.41) | LMNASLC29A1CDK1KMT2ACYP1A2 | |
| SCHEMBL30560030 | 0.86 | YTHDC1 (0.41) | LMNASLC29A1CDK1KMT2ACYP1A2 | |
| SCHEMBL30560033 | 0.86 | YTHDC1 (0.41) | LMNASLC29A1CDK1KMT2ACYP1A2 | |
| SCHEMBL17494542 | 0.85 | LMNA (0.61) | LMNASLC29A1ADORA3ADORA1GAA | |
| SCHEMBL16094623 | 0.80 | LMNA (0.54) | LMNAADORA3ADORA1KMT2AMAPT | |
| SCHEMBL30560020 | 0.80 | KMT2A (0.49) | LMNASLC29A1KMT2AMAPTCYP1A2 | |
| SCHEMBL20164572 | 0.80 | KMT2A (0.49) | LMNASLC29A1KMT2AMAPTCYP1A2 | |
| SCHEMBL20164318 | 0.79 | CDK2 (0.38) | SLC29A1CDK1GAAHTT | |
| SCHEMBL20164317 | 0.79 | CDK2 (0.38) | SLC29A1CDK1GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3316890-B1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME | NEURAD LTD (IL) | 2023-09-06 | — | — | EP | disclosed |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | NEURAD LTD. (IL) | 2019-05-21 | — | — | US | disclosed |
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | NEURAD LTD. (IL) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | MTNR1B, CHRM3, PER2 | LMNA 1394/4885SLC29A1 4472/4885ADORA3 274/4885 |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | MTNR1B, PDE3A, CHRM3 | LMNA 1200/4885SLC29A1 4518/4885ADORA3 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.